1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmerging Markets 2016-2020

Pharmerging Markets 2016-2020

  • November 2015
  • -
  • Infiniti Research Limited
  • -
  • 104 pages

Market outlook of the pharmerging markets
Technavio’s research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases.
The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.
Segmentation and analysis of the pharmerging markets
- Tier I countries (China)
- Tier II countries (Brazil, India, and Russia)
- Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)

The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China.

Competitive landscape and key vendors
The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The leading vendors in the market are -
- AstraZeneca
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Sanofi
Other prominent vendors in the market include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the pharmerging markets?
- What are the key market trends impacting the growth of the pharmerging markets?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the vendors in the pharmerging markets?
- Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries?
- What are the key outcomes of the five forces analysis of the pharmerging markets?
Technavio also offers customization on reports based on specific client requirement.

Related reports:
- Global Pharmaceutical Packaging Market 2015-2019
- Global Active Pharmaceutical Ingredients Market 2015-2019
- Global Pharmaceuticals Wholesale and Distribution Market 2015-2019
- Pharmaceutical Packaging Market in Europe 2015-2019
- Pharmaceutical Packaging Market in North America 2015-2019
- Pharmaceutical Logistics Market in the APAC 2015-2019
- Active Pharmaceutical Ingredients (API) Market in India 2015-2019

Table Of Contents

Pharmerging Markets 2016-2020
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Global pharmaceuticals market
Market size and forecast
PART 06: Pharmerging markets
PART 07: Market landscape
Market size and forecast
Five forces analysis
PART 08: Market segmentation based on geography
PART 09: Market overview of Tier I countries
China
PART 10: Market overview of Tier II countries
Brazil
Russia
India
PART 11: Market overview of Tier III countries
Market size and forecast
PART 12: Market drivers
Social and private health insurance
Increase in healthcare spending
High incidence of diseases
Impact of patent cliff on mature markets
PART 13: Impact of drivers
PART 14: Market challenges
Affordability and access
High competition
Partial regulatory policies
Price pressure
PART 15: Impact of drivers and challenges
PART 16: Market trends
Strategic alliances
Increase in generic sales
Mergers and acquisitions
Early drug launches in pharmerging markets
PART 17: Vendor landscape
Competitive scenario
AstraZeneca
GlaxoSmithKline
Merck
Novartis
Pfizer
Sanofi
Other prominent vendors
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio

List of Exhibits
Exhibit 01: Global pharmaceuticals market 2015-2020 ($ billions)
Exhibit 02: Drivers, challenges, and trends in global pharmaceuticals market
Exhibit 03: Share of pharmerging markets in global pharmaceuticals market 2015
Exhibit 04: Pharmerging markets 2015-2020 ($ billions)
Exhibit 05: Shares of pharmerging markets in global pharmaceuticals market 2015-2020
Exhibit 06: Shares of Tier I, II, and III countries in pharmerging markets 2015-2020
Exhibit 07: Pharmerging market shares by country 2015
Exhibit 08: Shares of pharmerging markets in global pharmaceuticals market 2015 and 2020
Exhibit 09: Five forces analysis
Exhibit 10: Pharmerging markets by geography
Exhibit 11: Tier I: Geographical representation
Exhibit 12: Major therapy areas by drug sales 2015
Exhibit 13: Pharmaceuticals market in China 2015-2020 ($ billions)
Exhibit 14: Pharmaceuticals market in China: SWOT analysis
Exhibit 15: Geographic representation of Tier II countries
Exhibit 16: Pharmaceuticals market in Tier II countries 2015-2020 ($ billions)
Exhibit 17: Pharmaceuticals market in Brazil 2015-2020 ($ billions)
Exhibit 18: Pharmaceuticals market in Brazil: SWOT analysis
Exhibit 19: Pharmaceuticals market in Russia 2015-2020 ($ billions)
Exhibit 20: Pharmaceuticals market in Russia: SWOT analysis
Exhibit 21: Major therapy areas by drug sales 2015
Exhibit 22: Major acquisitions in pharmaceuticals sector in India
Exhibit 23: Pharmaceuticals market in India 2015-2020 ($ billions)
Exhibit 24: Pharmaceuticals market in India: SWOT analysis
Exhibit 25: Geographic representation of Tier III countries
Exhibit 26: Pharmaceuticals market in Tier III countries 2015-2020 ($ billions)
Exhibit 27: Revenue for select Tier III countries 2015 ($ billions)
Exhibit 28: Tier III countries' pharmaceuticals market: SWOT analysis
Exhibit 29: Impact of drivers
Exhibit 30: Impact of drivers and challenges
Exhibit 31: AstraZeneca: Business segmentation based on revenue 2014
Exhibit 32: AstraZeneca: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 33: AstraZeneca: Geographical segmentation based on revenue 2014
Exhibit 34: AstraZeneca: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 35: AstraZeneca: SWOT analysis
Exhibit 36: GlaxoSmithKline: Business segmentation based on revenue 2014
Exhibit 37: GlaxoSmithKline: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 38: GlaxoSmithKline: Geographical segmentation based on revenue 2014
Exhibit 39: GlaxoSmithKline: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 40: GlaxoSmithKline: SWOT analysis
Exhibit 41: Merck: Business segmentation based on revenue 2014
Exhibit 42: Merck: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 43: Merck: Geographical segmentation based on revenue 2014
Exhibit 44: Merck: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 45: Merck: SWOT analysis
Exhibit 46: Novartis: Business segmentation based on revenue 2014
Exhibit 47: Novartis: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 48: Novartis: Geographical segmentation based on revenue 2014
Exhibit 49: Novartis: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ millions)
Exhibit 50: Novartis :SWOT analysis
Exhibit 51: Pfizer: Business segmentation based on revenue 2014
Exhibit 52: Pfizer: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 53: Pfizer: Geographical segmentation based on revenue 2014
Exhibit 54: Pfizer: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 55: Pfizer: SWOT analysis
Exhibit 56: Sanofi: Business segmentation based on revenue 2014
Exhibit 57: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 58: Sanofi: Geographical segmentation based on revenue 2014
Exhibit 59: Sanofi: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 60: Sanofi: SWOT analysis

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.